1. Lymphovascular space invasion as a prognostic factor of epithelial ovarian cancer: a multicenter study by the FRANCOGYN group
- Author
-
Xavier Carcopino, Vincent Lavoué, Cyrille Huchon, Camille Mimoun, Gilles Body, Julien Cirier, Pierre Collinet, Marcos Ballester, Yohann Dabi, Sofiane Bendifallah, Geoffroy Canlorbe, Jerome Lorenzini, Alexandre Bricou, Cherif Akladios, Charles Coutant, Lobna Ouldamer, Pierre-Adrien Bolze, Cyril Touboul, Service de Gynécologie-Obstétrique, Centre Olympe de Gouge, Centre Expert en Endométriose [CHU Tenon] (GRC6 C3E), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, CHU Strasbourg, Département de chirurgie, CRLCC Eugène Marquis (CRLCC), Hospices Civils de Lyon (HCL), Service de gynécologie-obstétrique [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Institut méditerranéen de biodiversité et d'écologie marine et continentale (IMBE), Centre National de la Recherche Scientifique (CNRS)-Institut de recherche pour le développement [IRD] : UMR237-Aix Marseille Université (AMU)-Avignon Université (AU), and Avignon Université (AU)-Aix Marseille Université (AMU)-Institut de recherche pour le développement [IRD] : UMR237-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Oncology ,medicine.medical_specialty ,Prognostic factor ,[SDV]Life Sciences [q-bio] ,Carcinoma, Ovarian Epithelial ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Overall survival ,Humans ,Neoplasm Invasiveness ,In patient ,Epithelial ovarian cancer ,ComputingMilieux_MISCELLANEOUS ,Neoplasm Staging ,Retrospective Studies ,Ovarian Neoplasms ,030219 obstetrics & reproductive medicine ,business.industry ,Obstetrics and Gynecology ,General Medicine ,Prognosis ,medicine.disease ,Lymphovascular ,Endometrial Neoplasms ,3. Good health ,Predictive factor ,Multicenter study ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Female ,Ovarian cancer ,business - Abstract
The presence of lymphovascular space invasion (LVSI) is not yet included in international recommendations neither as a prognostic factor nor as a parameter for the decision to use adjuvant chemotherapy in FIGO stage I/IIa ovarian cancer (OC).This study set out to evaluate the impact of LVSI on Overall Survival (OS) and Recurrence-Free Survival (RFS) in patients managed for epithelial OC.Retrospective multicenter study by the research group FRANCOGYN between January 2001 and December 2018. All patients managed for epithelial OC surgery and for whom histological slides for the review of LVSI were available, were included. The characteristics of patients with LVSI (LVSI group) were compared to those without LVSI (No-LVSI group). A Cox analysis for OS and RFS analysis was performed in all the populations.French multicenter tertiary care centers RESULTS: Over the study period, 852 patients were included in the 13 institutions. Among them, 289 patients had LVSI (33.9%). There was a significant difference in the distribution of LVSI between early and advanced stages (p 0.001). LVSI was an independent predictive factor for poorer Overall and Recurrence-Free Survival. LVSI affected OS (p 0.001) and RFS (p 0.001), LVSI affected OS and RFS for early stages (p = 0.001; p = 0.001, respectively) and also for advanced stages (p = 0.01; p = 0.009, respectively).The presence of LVSI in epithelial ovarian epithelial tumors has an impact on OS and RFS and should be included in the routine pathology examination to adapt therapeutic management, especially for women in the early stages of the disease.
- Published
- 2021